Guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties

• Published in: Regulatory toxicology and pharmacology Vol. 111; p. 104546
• Main Authors: De Jong, W.H., Borges, T., Ion, R.M., Panagiotakos, D., Testai, E., Vermeire, T., Bernauer, U., Rousselle, C., Bégué, Sté, Kopperud, H.M., Milana, M.R., Schmidt, T., Pignatti, F., Stoyanova, E., Volk, K., Bertollini, R., De Voogt, P., Duarte-Davidson, R., Hoet, P., Kraetke, R., Proykova, A., Samaras, T., Scott, M., Slama, R., Vighi, M., Zacharo, S.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.03.2020; Elsevier
• Subjects: Benefit-risk assessment; CMR/ED phthalates; Guidelines; Life Sciences; Medical devices; Santé publique et épidémiologie; SCHEER; CMR/ED phthalates; Medical devices; Benefit-risk assessment; SCHEER; Guidelines
• ISSN: 0273-2300; 1096-0295
• DOI: 10.1016/j.yrtph.2019.104546

By the new Medical Device Regulation (MDR, EU 2017/745) the use of certain phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties, above 0.1% by weight (w/w) is only allowed after a proper justification. The SCHEER provide Guidelines on the benefit-risk assessment (BRA) of the presence of such phthalates in certain medical devices. The Guidelines describe the methodology on how to perform a BRA for the justification of the presence of CMR/ED phthalates in medical devices and/or or parts or materials used therein at percentages above 0.1% w/w. They also describe the evaluation of possible alternatives for these phthalates used in medical devices, including alternative materials, designs or medical treatments. Relevant stakeholders e.g. manufacturers, notified bodies and regulatory bodies, can use the guidelines. The approach of these guidelines may also be used for a BRA of other CMR/ED substances present in medical devices. SCHEER noticed that a number of BRA methodologies are theoretically available. However, there is a considerable lack of data needed for the BRA for potential relevant alternatives to be used in medical devices. Therefore, SCHEER encourages manufacturers to generate data of high quality on such alternatives for CMR/ED phthalates in medical devices. •The guidelines provide a framework to perform a BRA to justify the presence of CMR or ED phthalates in medical devices.•They also describe the evaluation of possible alternatives for these phthalates used in medical devices.•Manufacturers are encouraged to generate data that are needed for the BRA on potential alternatives to be used in medical devices.